BLACK WEEKSViale −15 % · kompleti −10 % · ostalo −5 %s kodoBrezplačna dostava v Nemčiji od 200 €

Ta stran je bila prevedena samodejno in lahko vsebuje napake. Ste materni govorec? Veseli bomo vaših povratnih informacij in popravkov.Pošljite povratne informacije

The Peptide Desk The Peptide Desk
Reta + Cagri Blend, fotografija izdelka
GLP-1

Reta + Cagri Blend

GLP-1

  • Odprema iz Nemčije

Naročilo

Cena na kos - Brezplačna dostava v Nemčiji od 200 € med Black Weeks
  • DHL s sledenjem
  • Diskretna embalaža

4.6 od 5 na Trustpilotu73 ocen

Na prvi pogled

Reta + Cagri Blend v številkah

Ključni podatki iz našega leksikona.

Celoten vnos v leksikonu
Class
Triple agonistGLP-1 / GIP / glucagon, + amylin analog
Half-life
Retatrutide around 6 dayscagrilintide around 7 to 8 days
Form
Lyophilisatepowder, reconstituted with BAC water
Sizes
30 mg1 size in the shop

Za Reta + Cagri Blend še ni laboratorijske analize. Glasujte zanjDajte testirati sami, mi plačamo polovicoVse laboratorijske analize

Znanje

Vse o Reta + Cagri Blend

Priporočljivo zraven

Kaj potrebujete zraven

Bakteriostatska voda se samodejno doda v vašo košarico. Brizge in robčki z enim klikom.

Inzulinske brizge

10 kos. · 5.50 €

Alkoholni robčki

50 kos. · 10 €

Koliko vode?

Enote na brizgi za vašo velikost viale.

Odpri kalkulator →

FAQ

Pogosta vprašanja

Viri za vsak odgovor: vnos v leksikonu

Imate še vprašanje?

Pišite nam, naša ekipa vam bo pomagala.

Is the Reta + Cagri Blend approved or studied?

No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and cagrilintide together. Both components are in phase 3 and not approved.

Why Retatrutide and cagrilintide together?

Both act on different satiety pathways: Retatrutide on GLP-1, GIP and glucagon, cagrilintide on amylin receptors. With semaglutide as the partner, weight loss in a phase 1b trial after 20 weeks was 17.1 instead of 9.8 percent. For Retatrutide as the partner there are no data.

What do the studies of the components show?

Retatrutide alone: in TRIUMPH-1 after 80 weeks 25.0 percent less body weight on average at the highest study dose, 3.9 percent on placebo. Cagrilintide alone: up to 10.8 percent after 26 weeks in phase 2, 3.0 percent on placebo. In a substudy liver fat also fell sharply on Retatrutide.

Why is the cagrilintide share so small?

The vial contains five times as much Retatrutide as cagrilintide, because Retatrutide is the stronger and limiting part. Anyone going by the Retatrutide share stays far below the amounts used in the cagrilintide trials. Whether the small share contributes anything has not been studied.

How long do the components stay in the body?

Retatrutide had a half-life of about six days in a phase 1b study, cagrilintide 159 to 195 hours in another study, so about a week. Both fit one dose per week.

Which side effects were seen with the components?

With both, mainly gastrointestinal effects such as nausea and diarrhoea, depending on the dose. On Retatrutide heart rate rose in a dose-dependent way in phase 2. Two satiety signals together may strengthen nausea at the start, this has not been measured for this blend.

Which trials are still running?

Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The RENEW trials of cagrilintide alone run until 2027. No trial of the blend is listed in the registry.

Sorodno

Sorodni izdelki